Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours By Ogkologos - March 2, 2026 276 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PYNNACLE study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR 2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’ January 17, 2022 New on NCI’s Websites for June 2022 June 10, 2022 Dealing With Fears March 24, 2021 Should CAR T Cells Be Used Earlier in People with Non-Hodgkin... January 13, 2022 Load more HOT NEWS How to Get Started With Meditation During Cancer The Unique Challenges Teenagers and Young Adults With Cancer Face: An... FDA Grants Accelerated Approval to Pembrolizumab for HER2-positive Gastric Cancer EMA Recommends Granting a Marketing Authorisation for Tislelizumab
